Comparison of the detecting capability between 123I-mIBG and post-therapeutic 131I-mIBG scintigraphy for curie scoring in patients with neuroblastoma after chemotherapy

2021 ◽  
Author(s):  
Zhong-Ling Qiu ◽  
Shintaro Saito ◽  
Daiki Kayano ◽  
Hiroshi Wakabayashi ◽  
Seigo Kinuya
Keyword(s):  
Mibg Scintigraphy ◽  
131I Mibg

Diagnosis and Treatment of Neuroblastoma Using 131 l-Meta-lodobenzylguanidine

1986 ◽  
Vol 25 (05) ◽  
pp. 172-175 ◽  
Author(s):  
P. Frederiksen ◽  
J. Kamper ◽  
P. Jeppesen ◽  
C.-J. Edeling
Keyword(s):  
Tumor Regression ◽  
Absorbed Dose ◽  
Proper Treatment ◽  
Mibg Scintigraphy ◽  
131I Mibg ◽  
Tumor In Childhood ◽  
Curative Intention ◽  
And Control ◽  
Additional Tumor ◽  
Uncommon Tumor

Neuroblastoma is a lethal and not uncommon tumor in childhood. Early detection and display of the spread of the tumor is highly desirable for proper treatment. Nine children suspected of having neuroblastoma were examined by 131l-meta-iodobenzylguanidine (131I-MIBG) scintigraphy. In two recent studies 123l-meta-iodobenzylguanidine (123I-MIBG) was used. A primary adrenal neuroblastoma was correctly identified in 3 cases. In 2 patients additional tumor sites were found. In one patient, who was in complete remission, no pathological accumulation of 131I-MIBG was found. 131I-MIBG scintigraphies were also normal in 4 patients with other types of tumor. In one girl with a large adrenal neuroblastoma high uptake of 131I-MIBG was observed. She received two therapy doses of 131I-MIBG (1300–2800 MBq) with curative intention giving a total absorbed dose in the tumor of approximately 90 Gy. In spite of high retention of radioactivity in the tumor, regression did not appear, but her general condition was improved. In the present study images of superior quality were obtained by 123I-MIBG scintigraphy. It is concluded that scintigraphy with 131I- or 123I-MIBG should be used for primary visualization and control of neuroblastomas.

Die Rolle der131J-Metajod-benzylguanidin-(MIBG-) Szintigraphie in der Diagnostik der intestinalen Karzinoide

1987 ◽  
Vol 26 (06) ◽  
pp. 263-267
Author(s):  
M. L. Sautter-Bihl ◽  
K. R. Wilhelm ◽  
B. Kimmig ◽  
H. Bihl
Keyword(s):  
Neuroendocrine Tumors ◽  
False Positive ◽  
Clinical Symptoms ◽  
Cell System ◽  
Carcinoid Tumors ◽  
Mibg Scintigraphy ◽  
Mibg Uptake ◽  
131I Mibg

lodine-131 metaiodobenzylguanidine (131I-MIBG) is concentrated in a variety of neuroendocrine tumors, such as pheochromocytoma and neuroblastoma. Other neuroendocrine tumors from the APUD-cell system such as carcinoid tumors, may posses this uptake capability as well. We investigated 11 patients suffering from intestinal carcinoid with 131I-MIBG in order to determine the value of MIBG scintigraphy in these tumors. MIBG scans were positive in 5 out of 11 patients (45%). False-positive MIBG-scans did not occur. No correlation between MIBG uptake, clinical symptoms and urinary 5-HIAA level could be found.

Use of 131I-MIBG Scintigraphy in the Evaluation of Suspected Pheochromocytoma

1985 ◽  
Vol 60 (5) ◽  
pp. 299-304 ◽  
Author(s):  
STEPHEN J. SWENSEN ◽  
MANUEL L. BROWN ◽  
SHELDON G. SHEPS ◽  
GLEN W. SIZEMORE ◽  
HOSSEIN GHARIB ◽  
...  
Keyword(s):  
Mibg Scintigraphy ◽  
131I Mibg

scholarly journals A case of multiple extra-adrenal pheochromocytoma diagnosed by (131I) meta-iodobenzylguanidine ((131I) MIBG) scintigraphy and nuclear magnetic resonance (NMR).

1986 ◽  
Vol 75 (8) ◽  
pp. 1102-1108
Author(s):  
Junko SASAKI ◽  
Hironori YAMADA ◽  
Takashi FUJISAWA ◽  
Yasuhiro KAWAHARA ◽  
Yuichi ISHIKAWA ◽  
...  
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Mibg Scintigraphy ◽  
Adrenal Pheochromocytoma ◽  
131I Mibg ◽  
Nuclear Magnetic

scholarly journals Erratum to: Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

2015 ◽  
Vol 49 (2) ◽  
pp. 152-152
Author(s):  
Teik Hin Tan ◽  
Boon Nang Lee ◽  
Zanariah Hussein ◽  
Fathinul Fikri Ahmad Saad ◽  
Ibrahim Lutfi Shuaib
Keyword(s):  
Fdg Pet ◽  
Diagnostic Performance ◽  
Mibg Scintigraphy ◽  
Pet Ct ◽  
131I Mibg ◽  
18F Fdg ◽  
Fdg Pet Ct

Computed Tomography and 131I-MIBG Scintigraphy in the Diagnosis of Pheochromocytoma

1986 ◽  
Vol 27 (3) ◽  
pp. 305-309 ◽  
Author(s):  
M. Koizumi ◽  
K. Endo ◽  
H. Sakahara ◽  
T. Nakashima ◽  
Y. Nakano ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Prospective Study ◽  
Adrenal Glands ◽  
Adrenal Tumor ◽  
Ct Scans ◽  
Mibg Scintigraphy ◽  
Adrenal Pheochromocytoma ◽  
131I Mibg ◽  
A Prospective Study ◽  
Adrenal Ct

In order to evaluate the usefulness of computed tomography (CT) and 131I meta-iodobenzylguanidine (131I-MIBG) scintigraphy for the localization of pheochromocytoma, a prospective study was undertaken in 23 patients with possible pheochromocytoma. Seventeen tumors were identified in 13 patients. Two tumors were extra-adrenal. CT was superior for locating tumors in the adrenal glands while 131I-MIBG scintigraphy was more useful in the detection of extra-adrenal pheochromocytoma. Together with adrenal and extra-adrenal pheochromocytoma, the sensitivity for locating the tumor was calculated as 82 per cent (14/17) for CT and 76 per cent (13/17) for 131I-MIBG scintigraphy, respectively. One adrenal tumor (1 cm in size) only was missed by both methods. No false positive CT scans of 131I-MIBG scintigraphy were obtained in the remaining 10 patients who had possible pheochromocytoma but were excluded. These results indicated that CT and 131I-MIBG scintigraphy were both useful tools for detecting pheochromocytoma. References

scholarly journals Complementary roles of CT and 131I-MIBG scintigraphy in diagnosing pheochromocytoma

1983 ◽  
Vol 141 (4) ◽  
pp. 719-725 ◽  
Author(s):  
IR Francis ◽  
GM Glazer ◽  
B Shapiro ◽  
JC Sisson ◽  
BH Gross
Keyword(s):  
Mibg Scintigraphy ◽  
131I Mibg

scholarly journals Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 663
Author(s):  
Hiroshi Wakabayashi ◽  
Daiki Kayano ◽  
Anri Inaki ◽  
Raita Araki ◽  
Rie Kuroda ◽  
...  
Keyword(s):  
High Risk ◽  
Residual Disease ◽  
Whole Body ◽  
Primary Therapy ◽  
Consolidation Therapy ◽  
Mibg Scintigraphy ◽  
Diagnostic Use ◽  
131I Mibg ◽  
Post Therapy ◽  
Abnormal Uptake

123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. 131I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy 131I-mIBG scintigraphy may detect more lesions compared with diagnostic 123I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy 131I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic 123I-mIBG scintigraphy. We retrospectively examined the diagnostic utility of post-therapy 131I-mIBG scintigraphy in children who received 131I-mIBG as consolidation therapy. Nineteen children with complete response to primary therapy were examined. Post-therapy 131I-mIBG scintigraphy was performed four days after injection. The post-therapy 131I-mIBG scintigraphy, 4 children exhibited abnormal uptake on the WBS. Post-therapy 131I-mIBG SPECT/CT provided additional information in 2 cases. In total, 6 children exhibited abnormal uptake. The site of abnormal accumulation was on the recurrence site in one case, operation sites in five cases, and bone metastasis in one case. Post-therapy 131I-mIBG scintigraphy could detect residual disease that was not recognized using diagnostic 123I-mIBG scintigraphy in 32% of children with high-risk neuroblastoma and ganglioneuroblastoma. The diagnostic use of post-therapy 131I-mIBG scintigraphy can provide valuable information for detecting residual disease.

Sign in / Sign up

Export Citation Format

Share Document